Table 2.
Diagnostic-prognostic implications of NG2/CSPG4 expression in hematological malignancies1
| Leukemia | Age group | NG2/CSPG4 positive cases2 (out of n) |
NG2/CSPG4 positivity vs prevalent FAB status/Phenotype of MLL rearranged cases |
NG2/CSPG4 positivity in MLL germline cases (out of n) |
NG2/CSPG4 positivity in MLL rearranged cases (out of n) |
Disease course | References |
|---|---|---|---|---|---|---|---|
| ALL | Infant | 9% (104) | 56% pro-B; 33% pre-B; 11% T-ALL | 0% (89) | 100% (9) | ND | 96 |
| AML | Infant | 11% (166) | 67% M5 | 0% (85) | 78% (18) | Poor | 95 |
| AML | Infant | 35% (37) | 58% M4/M5 | 0% (13) | 54% (24) | Unaffected | 97 |
| AML | Infant/Adult | 43% (14) | 75% M5 | 0% (25) | 43% (14) | ND | 98 |
| AML/ ALL |
Infant/Adult | 14% (533) | NS 25% myeloid/NK cell ALL; 16% pro-/pre-B- ALL |
2% (12) | 81% (72) | ND | 99 |
| ALL | Adult | 23% (313) | 78 pro-B, 11% pre-B | 19% (48) | 89% (72) | ND | 102 |
| AML/ ALL |
Infant | 82% (11) | NS | ND | 100% (9) | Poor | 103 |
| ALL | Adult | 95% (184) | 100% pro-/pre-B | 15% (66) | 91% (118) | ND | 104 |
| AML | Adult | 23% (70) | 50% M5 | 29% (62) | 63% (8) | Poor | 107 |
| AML/ ALL |
Infant | 48% (311) | NS 90% pro-B, 6% T-ALL |
58% (143) | 42% (143) | ND | 100 |
1As established by flow cytometry using the reference mAb 7.1;
2Adopted average cut-off was >25% of leukemic blasts;
3NG2/CSPG4 expression has also been documented in one case of DC2/NK cell ALL 105;
Abbreviations: NS = not specified; ND = not determined.